ITGAM and neoplasm: While prior studies established the role of β‐glucan or BCG in inducing trained immunity against infections,[1, 25] our work uniquely identifies KK2DP7 as the first synthetic peptide adjuvant capable of specifically programming splenic CD11b+ myeloid cells to drive sustained anti‐tumor immunity.